TransMedics Shares Post Biggest Intraday Gain Since November 2023
TransMedics (TMDX) shares surged 25% on Nov. 6, the biggest intraday gain since November 2023. The rise came after Q3 results and an increased 2026 revenue outlook to $764M-$774M, up from $737M-$757M previously. The new forecast includes $14M from PAD Aviation.
How this was made

The 30-second read
Why it matters
The guidance lift and strong price reaction suggest short-term upside, but investors should monitor execution risks.
Market read
New revenue guidance and a sharp price move make this a notable event for traders focused on biotech and medical device stocks.
What to watch
Potential risks from PAD Aviation integration and competitive pressures are not detailed.
Background
TransMedics Group, a small-cap medical device company, announced Q3 results and raised its 2026 revenue guidance.
Ticker impact
TransMedics reported Q3 results and raised its 2026 revenue outlook to $764‑$774M, prompting a >25% intraday rally.
upward pressure as the market prices in higher revenue expectations
Revenue guidance increased by $30M and the stock already rallied 25% on the news, indicating strong investor reaction.
Market effects
May boost sentiment for the broader organ transplant device sector.
Limited to U.S. biotech/medical device investors.
Minimal global impact beyond niche market participants.
Counterpoint
Some investors may view the modest revenue increase as insufficient for a 25% rally, expecting a pullback.
Key entities
- companyTransMedics Group, Inc.
Medical device manufacturer reporting earnings and guidance.



